Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment Preferences for Somatuline Injector Devices: A Discrete Choice Experiment (DCE) of Patients With Neuroendocrine Tumors (NETs) and Nurses in the United States (US) and Canada

Next Previous
Trial Profile

Treatment Preferences for Somatuline Injector Devices: A Discrete Choice Experiment (DCE) of Patients With Neuroendocrine Tumors (NETs) and Nurses in the United States (US) and Canada

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 08 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Sponsors Ipsen

Most Recent Events

  • 30 Jan 2024 Status changed from recruiting to discontinued. Ipsen decided to discontinue development of this motorized device to avoid burden on the participants, because complex challenges had been identified during the recent testing phases.
  • 29 Sep 2023 Planned End Date changed from 31 Aug 2023 to 30 Nov 2023.
  • 29 Sep 2023 Planned primary completion date changed from 31 Aug 2023 to 30 Nov 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top